LOGO
LOGO

Monopar To Seek FDA Approval For Wilson Disease Drug In Early 2026

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

It's been a banner year so far for Monopar Therapeutics Inc. (MNPR), whose share price has catapulted as much as 145% this year.This clinical-stage company's lead drug candidate is ALXN1840, a once-daily, oral medicine in development for the treatment of Wilson disease.Wilson disease is a rare, progressive genetic disorder that disrupts the body's ability to eliminate excess copper, resulting in t...

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update: May 11 – May 15, 2026

May 15, 2026 15:25 ET
Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.

Latest Updates on COVID-19